MannKind | MNKD - Ebitda


MannKind reported $2.47M in EBITDA for its fiscal quarter ending in June of 2026.





Ebitda Change Date
Adma Biologics USD 55.44M 5.62M Jun/2026
BioCryst Pharmaceuticals USD 51.7M 30.14M Sep/2025
Eli Lilly USD 9.46B 3.54B Sep/2026
Halozyme Therapeutics USD 336.16M 7.34M Sep/2026
Insmed USD -80.97M 93.7M Sep/2026
Karyopharm Therapeutics USD -26.2M 1.83M Sep/2024
MacroGenics USD -64.54M 34.34M Jun/2026
MannKind USD 2.47M 461K Jun/2026
Merck USD 1.42B 2.97B Jun/2026
Minerva Neurosciences USD -4.36M 1.71M Sep/2024
Novavax USD 19.36M 190.79M Dec/2025
Novo Nordisk DKK 37.36B 31.84B Jun/2026
Pfizer USD 6.36B 350M Sep/2026
Sanofi EUR 5.79B 2.1B Sep/2026
Xencor USD 25.1M 59.73M Sep/2026